Cell based signal generation

• US 6,504,008 B1
• Filed: 02/01/1999
• Issued: 01/07/2003
• Est. Priority Date: 02/01/1999
• Status: Expired due to Fees

• Current Assignee: Cadus Technologies Incorporated
• Original Assignee: Cadus Technologies Incorporated
• Inventors: Xu, Jun, Trueheart, Joshua
• Primary Examiner(s): Guzo, David
• Assistant Examiner(s): LAMBERTSON, DAVID A
• Application Number:
  US09/241,888
• Time in Patent Office: 1,436 Days
• Field of Search: 435/5, 435/6, 435/254.2, 435/254.21, 536/23.1, 536/23.4, 536/23.5, 530/350, 530/371
• US Class Current: 530/350
• CPC Class Codes: C07K 14/39 from yeasts
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

The present invention makes available a rapid, reproducible, robust assay system for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular protein, e.g., a receptor or ion channel. The subject assay enables rapid screening of large numbers of compounds to identify those which act as an agonist or antagonist to the bioactivity of the cellular protein. In particular, the assay of the invention makes use of a cell that harbors a protein that is responsive to a cellular signal transduction pathway. The protein is operatively linked to a polypeptide which causes a detectable signal to be generated upon stimulation of the pathway, e.g., when a compound interacts with and modulates the activity of a cellular receptor or ion channel of the cell. Thus, the cell provides a signal generation means comprising a novel fusion protein the expression of which is independent of stimulation/activation of the signal transduction pathway, but the activity of which is responsive to the signal transduction pathway.

Claims

1. A fusion protein comprising Ste 5 operatively linked to Ras.

2. A fusion protein comprising Ste 11 operatively linked to His3.

3. A fusion protein comprising a polypeptide selected from the group consisting of a LexA DNA binding domain operatively linked to a B42 transcriptional activation domain operatively linked to Fus3;

a Gal4 DNA binding domain operatively linked to a B42 transcriptional activation domain operatively linked to Fus3; and

a Gal4 DNA binding domain operatively linked to a Gal4 transcriptional activation domnain II operatively linked to Fus3.

4. The fusion protein of claim 3 comprising a LexA DNA binding domain operatively linked to a B42 transcriptional activation domain operatively linked to Fus3.

5. The fusion protein of claim 3 comprising a Gal4 DNA binding domain operatively linked to a B42 transcriptional activation domain operatively linked to Fus3.

6. The fusion protein of claim 3 comprising a Gal4 DNA binding domain operatively linked to a Gal4 transcriptional activation domain II operatively linked to Fus3.